Small D - Search Results

1

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.

Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Brown P, et al. Among authors: small d. Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27. Blood. 2004. PMID: 15166029 Free article.

2

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Among authors: small d. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

3

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.

Zheng R, Friedman AD, Small D. Zheng R, et al. Among authors: small d. Blood. 2002 Dec 1;100(12):4154-61. doi: 10.1182/blood-2002-03-0936. Epub 2002 Aug 1. Blood. 2002. PMID: 12393674 Free article.

4

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD. Murphy KM, et al. Among authors: small d. J Mol Diagn. 2003 May;5(2):96-102. doi: 10.1016/S1525-1578(10)60458-8. J Mol Diagn. 2003. PMID: 12707374 Free PMC article.

5

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Among authors: small d. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963 Free article.

6

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Zheng R, et al. Among authors: small d. Blood. 2004 Mar 1;103(5):1883-90. doi: 10.1182/blood-2003-06-1978. Epub 2003 Oct 30. Blood. 2004. PMID: 14592841 Free article.

7

Novel FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Among authors: small d. Expert Opin Investig Drugs. 2003 Dec;12(12):1951-62. doi: 10.1517/13543784.12.12.1951. Expert Opin Investig Drugs. 2003. PMID: 14640939 Review.

8

Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.

Zheng R, Klang K, Gorin NC, Small D. Zheng R, et al. Among authors: small d. Leuk Res. 2004 Feb;28(2):121-6. doi: 10.1016/s0145-2126(03)00184-x. Leuk Res. 2004. PMID: 14654075

9

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Among authors: small d. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

10

Small molecule FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Among authors: small d. Curr Pharm Des. 2004;10(11):1183-93. doi: 10.2174/1381612043452604. Curr Pharm Des. 2004. PMID: 15078134 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,305 results

Search Page